Shin Nippon Biomedical Laboratories, Ltd. (FRA:YB3)

Market Cap	247.74M -36.0%
Revenue (ttm)	177.41M +0.3%
Net Income	24.91M -7.3%
EPS	0.60 -7.3%
Shares Out	n/a
PE Ratio	9.95
Forward PE	n/a
Dividend	0.28 (4.86%)
Ex-Dividend Date	Mar 30, 2026

Volume	n/a
Open	5.70
Previous Close	5.75
Day's Range	5.70 - 5.70
52-Week Range	5.70 - 10.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 11, 2026

About FRA:YB3

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation...

• Industry: Commercial Physical and Biological Research
• Founded: 1957
• Employees: 1,522
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: YB3

Financial Performance

In fiscal year 2026, FRA:YB3's revenue was 32.52 billion, an increase of 0.35% compared to the previous year's 32.41 billion. Earnings were 4.57 billion, a decrease of -7.26%.

Financial numbers in JPY